U.S. market Open. Closes in 5 hours 16 minutes

TARA | Protara Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 4.18 - 4.45
52 Week Range 1.5950 - 10.48
Beta 1.73
Implied Volatility 327.08%
IV Rank 57.51%
Day's Volume 377,155
Average Volume 288,259
Shares Outstanding 36,767,500
Market Cap 156,629,550
Sector Healthcare
Industry Biotechnology
IPO Date 2014-10-22
Valuation
Profitability
Growth
Health
P/E Ratio -1.96
Forward P/E Ratio N/A
EPS -2.17
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 26
Country USA
Website TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
*Chart delayed
Analyzing fundamentals for TARA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TARA Fundamentals page.

Watching at TARA technicals we can see that long-term trend is bullish, while middle-term trend is bearish, but short-term trend is bullish. More technicals details can be found on TARA Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙